Bruker Reports Second Quarter 2022 Financial Results

Q2 2022 reported revenue growth of 3.1% year-over-year (yoy); organic revenue growth of 8.8% Q2 2022 GAAP EPS $0.33; non-GAAP EPS $0.45, up 2.3% yoy Maintaining FY 2022 guidance for high, single-digit organic revenue growth, non-GAAP operating profit margin expansion and non-GAAP EPS increase BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced financial results... Read more

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology HILLSBORO, Ore.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a... Read more

PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company

Enters agreement with intention to divest Applied, Food and Enterprise Services businesses WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 1, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital,... Read more

Thermo Fisher Scientific Reports Second Quarter 2022 Results

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 2, 2022. Second Quarter 2022 Highlights Second quarter revenue was $10.97 billion. Second quarter GAAP diluted earnings per share (EPS) was $4.22. Second quarter adjusted EPS was $5.51. Delivered... Read more

Two PerkinElmer Tests Added to UK’s Updated NICE Diagnostic Guidance for Suspected Preterm Pre-Eclampsia

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a placental growth factor (PlGF) measurement using its DELFIA® Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA® Xpress sFlt-1 kit (CE-IVD), have been included in an updated diagnostic guidance issued by the United Kingdom’s National... Read more

PerkinElmer Elects Dr. Michelle McMurry-Heath to its Board of Directors

WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 22, 2022– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Dr. Michelle McMurry-Heath has been elected to its board of directors, effective July 22, 2022. “I am pleased to welcome Michelle to PerkinElmer’s board and excited to see the Company benefit from both her... Read more